Abstract

Objective: Most untreated hepatitis C virus (HCV) patients develop chronic infection and severe complications, including death. Direct-acting antivirals in early stages of liver fibrosis reduce complications and healthcare costs. However, therapy is often delayed, and patients in early stages have limited access to effective treatments. We assessed the clinical and economic effect of treating chronic HCV at early versus late stages of disease in Argentina.

Methods: A Markov model of the natural HCV history was used to forecast lifetime liver-related and economic outcomes from social security sector perspective. Healthcare use and transition probabilities were drawn from literature. Demographic characteristics of the patients and treatment attributes were based on data from registrational trials of glecaprevir/pibrentasvir.

Results: Lower rates of all hepatic complications and liver-related mortality were predicted when treatment was initiated in mild versus advanced disease. Sustained virologic response rates were similar among all stages. Higher quality-adjusted life years (QALYs) were predicted when treatment was initiated in mild (F0-F1) versus moderate (F2-F3) or advanced (F4) liver disease (11.5, 9.9, and 7.5 QALYs, respectively). Delaying treatment increased long-term total lifetime costs (F4: AR$ 1 437 816; F2-F3: AR$ 967 673; F0-F1: AR$ 954 018; 37.10 AR$=1 USD, Nov 2018 exchange rate) and provided fewer QALYs.

Conclusions: Our study show early treatment was a dominant strategy compared with treatment in advanced stages of liver disease. These results may help health policy makers take actions to reduce health and economic burden of HCV in Argentina.

Keywords: Hepatitis C virus, cost-effectiveness, direct-acting antiviral, pan-genotype, Argentina

1. Introduction

Hepatitis C virus (HCV) infection is considered a highly important healthcare problem (World Health Organization [WHO], 2017). This transmissible viral infection usually remains asymptomatic in the disease early stages but may lead to serious complications, including compensated cirrhosis (CC) and decompensated cirrhosis (DCC), hepatocellular carcinoma (HCC), and liver failure linked to significant morbidity and mortality rates (Moreno et al., 2017). The cost burden derived from HCV is associated with hepatic complications, as well as severe extrahepatic complications (eg, type 2 diabetes mellitus, depression and cognitive impairment, renal insufficiency, non-Hodgkin lymphoma) (Reau, Vekeman, Wu, & Sánchez-González, 2017).

The global prevalence rate of HCV infection has been estimated at 1% by the World Health Organization (WHO, 2017). Data from Argentina are scarce, and the exact HCV prevalence rate remains unknown; it has been calculated at 0.8%, according to several studies, ranging from 0.17% to 5.6%. However, in high endemic areas,
prevalence may be higher. Most data have been obtained by extrapolation and may not represent the real HCV infection prevalence (Ridruejo et al., 2016).

The main goal of antiviral treatment of HCV is to achieve sustained virologic response (SVR), defined as an absence of detectable HCV RNA ≥12 weeks after treatment (Pearlman & Traub, 2011). The choice of the best treatment scheme for each individual patient depends on the clinical situation, presence of comorbidities, use of concomitant treatments, evaluation of liver damage, HCV genotype/subtype, and treatment efficiency. Currently, direct-acting antivirals (DAAs) are the reference therapies for chronic HCV in Argentina (Asociación Argentina para el Estudio de las Enfermedades del Hígado [AAEEH], 2020). HCV treatment can be very effective, especially if HCV is diagnosed in the early stages of the infection (Alomar et al., 2018). In addition, HCV treatment in early stages of the disease was associated with decreased liver-related complications and healthcare costs when compared with treatment in later stages of liver fibrosis (Pearlman & Traub, 2011; Reau, Vekeman, Wu, & Sánchez-González, 2017). Nevertheless, treatment start is often delayed due to several factors (patient level: lack of awareness, fear of side effects, poor adherence, and comorbidities; provider level: limited knowledge, lack of availability, and communication difficulties; payer level: lack of promotion, surveillance, and costs) (Mendizábal, Alonso, & Silva, 2019). As a consequence, patients in early fibrosis stages may have restricted access to effective treatment regimens. Specific actions to increase accessibility to HCV diagnosis and timely treatment are still pending in most Latin American countries, including Argentina. It is estimated that less than one-third of infected patients have been diagnosed (Kershenobich et al., 2011); according to recent epidemiologic data, only 8.9% of diagnosed patients currently are being treated in Latin America (Viola et al., 2020).

The combination of glecaprevir (GLE 300 mg, a NS3/4A protease inhibitor) and pibrentasvir (PIB 120 mg, a NS5A viral protein inhibitor) administered once daily is indicated for the treatment of adult patients with genotypes 1 to 6 HCV chronic infection with or without CC. According to current guidelines, this pangenotypic scheme is indicated in an 8-week schedule in selected populations (AAEEH, 2020).

Availability of optimized treatment schemes may lead to even better responses with the goal of a complete eradication of this disease. However, there is a need to evaluate the financial healthcare impact of DAA schemes. In the present study, we assessed the clinical and economic consequence of treating patients with HCV at early versus late stages of liver disease in Argentina.

2. Method

A Markov model of the natural history of HCV was used to forecast liver-related and economic outcomes over a lifetime; the model scheme has been described elsewhere (Liu et al., 2012). The model was run from the perspective of Argentina’s social security sector, which represents approximately one-third of the total healthcare system. The social security sector in Argentina covers all employers of the formal economy and their families, is financed with payroll contributions of employers and employees, and often operates through contracts with private providers (Bello & Becerril-Montekio, 2011). Healthcare use and transition probabilities were drawn from published literature (Bardach et al., 2019; Saraswat et al., 2015). Demographic characteristics of the patients and treatment attributes were based on data from clinical trials of GLE/PIB (Forns et al., 2017; Wyles et al., 2018; Asselah et al., 2018; Zeuzem et al., 2018).
Analyses were performed for patients with all HCV genotypes and distinct fibrosis stages of liver disease, defined by Metavir score: mild (F0: no fibrosis; F1: portal fibrosis without septa), moderate (F2: portal fibrosis with few septa; F3: numerous septa with incomplete nodules), and severe disease (F4: CC), both in naive or treatment-experienced patients (Bedossa & Poynard, 1996). DCC, HCC, and need for liver transplantation were also included. Without treatment, spontaneous viral clearance is only possible from F0 stage. Death may occur in any model stage (Figure 1). The main demographic and virologic data of naive and treatment-experienced patients are shown in Table 1.

Table 1. Demographic characteristics

| Variable            | Patients treatment-naive | Patients treatment experienced |
|---------------------|--------------------------|-------------------------------|
| Percentage of patients | 75                       | 25                            |
| Age, years          | 44.15                    | 56                            |
| Male sex, %         | 57.7                     | 58.6                          |
| GT distribution, %  |                          |                               |
| GT1                 | 59.0                     |                               |
| GT1a                | 34.5                     |                               |
| GT1b                | 65.5                     |                               |
| GT2                 | 22.0                     |                               |
| GT3                 | 18.0                     |                               |
| GT4                 | 1.0                      |                               |
| GT5 and 6           | 0.0                      |                               |

Abbreviations: GT, genotype.

Probability rates of fibrosis progression and health condition were obtained from available literature (Table 2) (Thein, Yi, Dore, & Krahn, 2008; Wright et al., 2006; Shepherd et al., 2007; Hartwell, Jones, Baxter, & Shepherd, 2011).
Table 2. Model inputs for the base case and PSA

| Variable | Base-case value | Sensitivity Low | Sensitivity High | Distribution in PSA |
|----------|-----------------|-----------------|------------------|---------------------|
| **Transitional probabilities (annual)** | | | | |
| **Fibrosis Progression** | | | | |
| F0 to F1 | 0.110 | 0.088 | 0.132 | Beta |
| F1 to F2 | 0.088 | 0.070 | 0.105 | Beta |
| F2 to F3 | 0.176 | 0.141 | 0.211 | Beta |
| F3 to F4 (CC) | 0.143 | 0.114 | 0.172 | Beta |
| **Non-fibrosis Disease Progression** | | | | |
| SVR, history of F4 (CC) to HCC (first year) | 0.012 | 0.003 | 0.022 | Beta |
| CC to DCC | 0.039 | 0.029 | 0.049 | Beta |
| CC to HCC (First Year) | 0.014 | 0.004 | 0.024 | Beta |
| DCC to HCC (First Year) | 0.014 | 0.004 | 0.024 | Beta |
| **Liver Transplant** | | | | |
| DCC to Liver Transplant (First Year) | 0.020 | 0.016 | 0.024 | Beta |
| HCC to Liver Transplant (First Year) | 0.020 | 0.016 | 0.024 | Beta |
| **Liver-related Mortality** | | | | |
| DCC to Liver Death | 0.130 | 0.120 | 0.140 | Beta |
| Liver Transplant to Liver Death | 0.150 | 0.120 | 0.180 | Beta |
| After Liver Transplant to Liver Death | 0.057 | 0.046 | 0.068 | Beta |
| HCC to Liver Death | 0.430 | 0.400 | 0.460 | Beta |
| **Health state utilities** | | | | |
| Mild fibrosis (F0 – F1) | 0.770 | 0.616 | 0.924 | Beta |
| Moderate fibrosis (F2 – F3) | 0.660 | 0.528 | 0.792 | Log-normal |
| Severe fibrosis, F4 (CC) | 0.550 | 0.440 | 0.660 | Log-normal |
| No HCV | 0.820 | NA | NA | NA |
| SVR, history of mild fibrosis | 0.820 | NA | NA | NA |
| SVR, history of moderate fibrosis | 0.710 | NA | NA | NA |
| SVR, history of severe fibrosis (CC) | 0.600 | NA | NA | NA |
| DCC | 0.450 | 0.360 | 0.540 | Beta |
| HCC | 0.450 | 0.360 | 0.540 | Beta |
| Liver transplant (first year) | 0.450 | 0.360 | 0.540 | Beta |
| Liver transplant (subsequent year) | 0.670 | 0.536 | 0.804 | Beta |

Abbreviations: F0-F1: mild liver disease (no fibrosis-portal fibrosis without septa); F2-F3: moderate liver disease (portal fibrosis with few septa-numerous septa with incomplete nodules); F4: severe liver disease (compensated cirrhosis); GT, genotype; SVR, sustained virologic response; CC, compensated cirrhosis; DCC, decompensated cirrhosis; HCC, hepatocellular carcinoma; NA, not applicable.

Health outcomes included lifetime risk of CC, DCC, HCC, liver transplantation, and liver-related death. Other outcomes included lifetime costs and quality-adjusted life years (QALYs), both discounted at a 5% rate, with a time horizon of 70 years (Augustovski et al., 2010; MERCOSUR, 2009). An analysis strategy with a portfolio approach was performed, considering a pangenotypic HCV patient population, regardless of treatment history and presence of cirrhosis. Costs of the model were obtained from reimbursement tariffs of the social security
institutions and expressed in Argentine pesos (exchange rate 37.10 AR$ = 1 USD, November 2018) (Table 3).

Table 3. Direct costs considered in our model

| Variable                                           | Base-case cost, AR$ | Sensitivity Low | Sensitivity High | Distribution in PSA |
|----------------------------------------------------|---------------------|-----------------|------------------|---------------------|
| **Direct medical cost for each health condition**  |                     |                 |                  |                     |
| Mild fibrosis (F0 – F1)                            | 1831                | 916             | 2747             | Gamma              |
| Moderate fibrosis (F2 – F3)                        | 1967                | 984             | 2951             | Gamma              |
| Severe fibrosis, F4 (CC)                           | 5076                | 2538            | 7614             | Gamma              |
| SVR, history of mild fibrosis                      | 1000                | 500             | 1501             | Gamma              |
| SVR, history of moderate fibrosis                  | 1416                | 708             | 2124             | Gamma              |
| SVR, history of severe fibrosis (CC)               | 4827                | 2414            | 7241             | Gamma              |
| DCC                                                | 96 629              | 48 314          | 144 943          | Gamma              |
| HCC (first year)                                   | 24 543              | 12 272          | 36 815           | Gamma              |
| HCC (subsequent years)                             | 14 942              | 7 471           | 22 413           | Gamma              |
| Liver transplantation (first year)                 | 356 244             | 178 122         | 534 366          | Gamma              |
| Liver transplantation (subsequent years)           | 37 826              | 18 913          | 56 740           | Gamma              |
| **Treatment cost**                                 |                     |                 |                  |                     |
| Drug cost (glecaprevir/pibrentasvir) by day         | 15 768              | NA              | NA               | NA                 |
| **Treatment-related costs**                        |                     |                 |                  |                     |
| Anemia                                             | 28 076              | 14 038          | 42 114           | Gamma              |
| Rash                                               | 119                 | 59              | 178              | Gamma              |
| Depression                                         | 9810                | 4905            | 14 715           | Gamma              |
| Neutropenia                                        | 7261                | 3630            | 10 891           | Gamma              |
| Thrombocytopenia                                   | 4694                | 2347            | 7 042            | Gamma              |

Abbreviations: PSA, probabilistic sensitivity analysis; SVR, sustained virologic response; CC, compensated cirrhosis; DCC, decompensated cirrhosis; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; NA, not applicable.

Probabilistic sensitivity analysis (PSA) was carried out to examine the robustness of model results. In the PSA, it was assumed that each input parameter are associated with a certain probabilistic distribution. The parameters of the variables considered in the PSA are shown in Table 2 and Table 3. For the PSA, 500 simulations were drawn from the variables’ distributions. The results are summarized graphically using the cost-effectiveness plane, where the horizontal axis indicates the total QALYs, and the vertical axis indicates the discounted total cost of each fibrosis stages of liver disease.

3. Results

In base-case, when treatment was initiated in milder versus advanced stages, lower rates of DCC, HCC, liver transplant, and liver-related death were predicted in HCV patients (Figure 2).
Figure 2. Lifetime risks of liver morbidity and mortality from GLE/PIB

DCC, decompensated cirrhosis; F0-F1: mild liver disease (no fibrosis-portal fibrosis without septa); F2-F3: moderate liver disease (portal fibrosis with few septa-numerous septa with incomplete nodules); F4/CC: severe liver disease/compensated cirrhosis; GLE/PIB, glecaprevir/pibrentasvir; HCC, hepatocellular carcinoma; LrD: liver-related death; LT: liver transplantation.

Rates of SVR were similar among patients with mild (F0-F1: 97.9%), moderate (F2-F3: 97.9%), and severe disease (F4-CC: 98.9%). Nevertheless, higher QALYs were predicted in the Markov model when GLE/PIB scheme was started at early stages, accounting for 11.5, 9.9, and 7.5 lifetime QALYs for mild, moderate, and advanced liver disease, respectively (Figure 3). Lower direct medical costs were also predicted in a context of early treatment with GLE/PIB when compared with patients starting therapy in moderate or advanced liver disease (F0-F1: AR$ 954,018; F2-F3: AR$ 967,673; and F4: AR$ 1,437,816).

Figure 3. Lifetime per-patient direct medical costs and QALYs from treatment with GLE/PIB
Exchange rate 37.10 AR$ = 1 USD, November 2018. Direct costs included extrahepatic complication. F0-F1: mild liver disease (no fibrosis-portal fibrosis without septa); F2-F3: moderate liver disease (portal fibrosis with few septa-numerous septa with incomplete nodules); F4: severe liver disease /compensated cirrhosis; GLE/PIB, glecaprevir/pibrentasvir; QALY, quality-adjusted life year.

Figure 4. Probability sensitivity analysis scatter plot of expected cost and QALYs

Exchange rate 37.10 AR$ = 1 USD, November 2018. Direct costs included extrahepatic complication. F0-F1: mild liver disease (no fibrosis-portal fibrosis without septa); F2-F3: moderate liver disease (portal fibrosis with few septa-numerous septa with incomplete nodules); F4: severe liver disease /compensated cirrhosis; GLE/PIB, glecaprevir/pibrentasvir; QALY, quality-adjusted life year.

Results of the PSA prove the robustness of the base-case findings. These confirm that treating chronic HCV infection at early fibrosis stages has better outcomes and lower total healthcare costs than treatment in the severe liver disease stage (Figure 4).

4. Discussion

Hepatitis C is considered a global public health problem. According to the Centers for Disease Control and Prevention, up to 70% of people infected with HCV will develop chronic liver disease, 5% to 20% will develop cirrhosis in a period of 20 to 30 years, and 1 to 5 subjects will die from cirrhosis or HCC (Stasi, Silvestri, & Voller, 2020). The World Health Organization recommends treating all persons with chronic HCV infection older than 12 years with pangenotypic DAAs, with the goal of cure (WHO, 2021). Evaluation of costs is highly relevant for inclusion of these treatment schemes in healthcare systems.

Although in Argentina there is no formal centralized and consolidated instance for health technology assessment, this type of analysis (integrating clinical information with economic data in connection with a new clinical intervention) is essential for rational decision-making that is not based only on implicit health coverage. In our study, which used a Markov model for the social security sector of the Argentine healthcare system, early treatment with GLE/PIB generated more QALYs at lower cost and was therefore a dominant strategy.

Our data showed that treating chronic HCV infection at early fibrosis stages has better health outcomes in terms of lifetime risks of DCC, HCC, liver transplantation, and liver-related mortality. In addition, early pangenotypic treatment with GLE/PIB was related to a reduction of total healthcare costs in Argentina, especially when comparing both mild and moderate stages with patients with F4 Metavir score or CC. This benefit in medical costs included extrahepatic complications of HCV.

Our results are in line with previously published research by other authors from developed countries (Ahmed,
In the United States, Ahmed et al. showed that treatment with a DAA at the F2 stage rather than F3-F4 is projected to have greater efficacy, decreasing the average number of cases of DCC by 63.3%, HCC by 89.0%, liver transplants by 83.3%, and HCV-related deaths by 84.5% (Ahmed, Gordon, Saab, & Younossi, 2014). Furthermore, Buti et al. reported similar results using a model in the Spanish setting. They showed that, when compared with delayed administration of therapy at the F4 stage, initiating DAA treatment at stages F2–F3 reduced the incidence of liver-disease complications and was associated with cost-savings for the Spanish National Health System in previously untreated patients with genotype 1 HCV (Buti et al., 2016).

In our model, the GLE/PIB treatment regimen has been associated with very high overall SVR rates in all stages of the disease, as previously reported in real-world studies (Hsu et al., 2019; Lampertico et al., 2020; Ridruejo et al., 2020). However, higher QALYs were predicted when treatment was started in mild stages versus moderate or advanced liver disease. The QALYs estimation is useful to assess both the effect of a treatment on life expectancy and quality of life (Ogden, 2017). As a consequence, QALYs represent time alive, scaled to reflect health state desirability (Neumann & Cohen, 2018).

Considering these data and that the coronavirus disease 2019 has placed a significant strain on national healthcare systems at a critical moment in the context of hepatitis elimination (WHO, 2016), this analysis may help decision makers to reprioritize programs and resources to achieve HCV elimination targets and reap the full benefits of early HCV treatment (Blach et al., 2021).

In conclusion, from a perspective of social security of Argentina, treating chronic HCV infection at early fibrosis stages improves health outcomes and reduces total healthcare costs. Our results may help public health authorities take actions to reduce the relevant health and economic burden of HCV in Argentina by avoiding delays and restrictions in HCV treatment accessibility.

Acknowledgments

Financial support for this study was provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the publication. All authors contributed to the development of the publication and maintained control over the final content. The authors wish to thank Romina de Marcos and Leonardo Gilardi, from Agencia Médica, for the medical writing support, which was funded by Abbvie.

Competing Interests Statement

The authors declare that Diego Kanevsky and Maria Florencia Rodriguez are employees of AbbVie Argentina and may own AbbVie stock or stock options. Yuri Sanchez Gonzalez is an employee of AbbVie Inc. and may own AbbVie stock or stock options. Mariana Glancszpigel is director of 3eff, a health consultancy that offers services for the pharmaceutical industry including Abbvie. She has given conferences for the pharmaceutical industry that also includes Abbvie. Natalia Albaytero is manager in 3eff, a consultancy that offers services for the pharmaceutical industry including Abbvie. She has no other financial relationships relevant to disclose. Jorge Elgart: advisor in 3Eff; no other financial relationships relevant to disclose. Manuel Mendizabal received speaker honoraria from Gador.

References

Ahmed, A., Gordon, S. C., Saab, S., & Younossi, Z. (2014, January). Evaluation of the health outcomes for ledipasvir/sofosbuvir in early vs. Delayed treatment according to fibrosis stage of patients with chronic hepatitis C virus (HCV) genotype 1 infection: results from a decision-analytic markov model. In Hepatology (Vol. 60, pp. 1041A-1041A). 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY-BLACKWELL.

Alomar, M. J., Al Zaabi, A. N., Hassan, N. A., Strauch, C. C., Al Zaabi, M. E., & Shahwan, M. J. (2018). Safety and Economic Evaluation of Patients Treated for Hepatitis with Antiviral Daclatasvir and Sofosbuvir Combined Vs. Ledipasvir/Sofosbuvir 90mg/400mg in a medical institution in The UAE. Journal of Pharmaceutical Sciences and Research, 10(3), 501-505.

Asociación Argentina para el Estudio de las Enfermedades del Hígado [AAEEH]. (2020). Recomendaciones para el Tratamiento de la Hepatitis por Virus C, Actualización 2020. Retrieved March 27, 2021, from https://bit.ly/36np1OE

Asselah, T., Kowdle, K. V., Zadeikis, N., Wang, S., Hassanein, T., Horsmans, Y., ... & Mensa, F. J. (2018). Efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis. Clinical Gastroenterology and Hepatology, 16(3), 417-426. https://doi.org/10.1016/j.cgh.2017.09.027
Augustovski, F., Garay, O. U., Pichon-Riviere, A., Rubinstein, A., & Caporale, J. E. (2010). Economic evaluation guidelines in Latin America: a current snapshot. Expert review of pharmacoeconomics & outcomes research, 10(5), 525-537. https://doi.org/10.1586/erp.10.56

Bardach, A., Hernández-Vásquez, A., Palacios, A., Calderón, M., Soto, N., Balan, D., & Augustovski, F. (2019). Epidemiología, consumo de recursos y costos del manejo médico de la Hepatitis C en Argentina, Colombia, Uruguay y Venezuela. Value in Health Regional Issues, 20, 180-190. https://doi.org/10.1016/j.vhri.2019.06.004

Bedossa, P., & Poynard, T. (1996). An algorithm for the grading of activity in chronic hepatitis C. Hepatology, 24(2), 289-293. https://doi.org/10.1002/hep.51024021

Belló, M., & Becerril-Montekio, V. M. (2011). The health system of Argentina. Salud publica de Mexico, 53, s96-s109.

Blach, S., Kondili, L. A., Aghemo, A., Cai, Z., Dugan, E., Estes, C., ... & Craxi, A. (2021). Impact of COVID-19 on global HCV elimination efforts. Journal of hepatology, 74(1), 31-36. https://doi.org/10.1016/j.jhep.2020.07.042

Buti, M., Domínguez-Hernández, R., Oyagüez, I., & Casado, M. Á. (2016). Cost–effectiveness analysis of sofosbuvir, peginterferon and ribavirin in patients with chronic hepatitis C: Early treatment in the initial stage of fibrosis vs. delayed treatment in advanced fibrosis. Gastroenterología y Hepatología (English Edition), 39(7), 449-457. https://doi.org/10.1016/j.gastrohep.2016.03.006

Forns, X., Lee, S. S., Valdes, J., Lens, S., Ghali, B., Aguilar, H., ... & Mensa, F. J. (2017). Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. The Lancet infectious diseases, 17(10), 1062-1068. https://doi.org/10.1016/S1473-3099(17)30496-6

Hartwell, D., Jones, J., Baxter, L., & Shepherd, J. (2011). Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. Health technology assessment (Winchester, England), 15(17), i. https://doi.org/10.3310/hta15170

Hsu, S. J., Chiu, M. C., Fang, Y. J., Yang, T. H., Yu, J. J., Chen, C. C., ... & Kao, J. H. (2019). Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C. Journal of the Formosan Medical Association, 118(8), 1187-1192. https://doi.org/10.1016/j.jfma.2019.06.014

Kershenobich, D., Razavi, H. A., Sánchez-Avila, J. F., Bessone, F., Coelho, H. S., Dagher, L., ... & Silva, M. (2011). Trends and projections of hepatitis C virus epidemiology in Latin America. Liver International, 31, 18-29. https://doi.org/10.1111/j.1478-3231.2011.02538.x

Lampertico, P., Carrión, J. A., Curry, M., Turnes, J., Cornberg, M., Negro, F., ... & Wedemeyer, H. (2020). Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis. Journal of Hepatology, 72(6), 1112-1121. https://doi.org/10.1016/j.jhep.2020.01.025

Liu, S., Cipriano, L. E., Holodniy, M., Owens, D. K., & Goldhaber-Fiebert, J. D. (2012). New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Annals of internal medicine, 156(4), 279-290. https://doi.org/10.7326/0003-4819-156-4-201202210-00005

Mendizabal, M., Alonso, C., & Silva, M. O. (2019). Overcoming barriers to hepatitis C elimination. Frontline Gastroenterology, 10(3), 207-209. https://doi.org/10.1136/flgastro-2018-101114

MERCOSUR. (2009). Directrices para la Evaluación Económica de Tecnologías en Salud. MERCOSUR/XXX SGT Nro. 11 P. RES. 06/09. Montevideo, X/2009. Retrieved March 27, 2021, from https://bit.ly/2PY19w1

Moreno, G. A., Wang, A., González, Y. S., Espinosa, O. D., Vania, D. K., Edlin, B. R., & Brookmeyer, R. (2017). Value of comprehensive HCV treatment among vulnerable, high-risk populations. Value in Health, 20(6), 736-744. https://doi.org/10.1016/j.jval.2017.01.015

Neumann, P. J., & Cohen, J. T. (2018). QALYs in 2018—advantages and concerns. Jama, 319(24), 2473-2474. https://doi.org/10.1001/jama.2018.6072

Nuño Solinís, R., Arratibel Ugarte, P., Rojo, A., & Sanchez Gonzalez, Y. (2016). Value of treating all stages of chronic hepatitis C: a comprehensive review of clinical and economic evidence. Infectious diseases and therapy, 5(4), 491-508. https://doi.org/10.1007/s40121-016-0134-x
Ogden, J. (2017). QALYs and their role in the NICE decision-making process. *Prescriber, 28*(4), 41-43. https://doi.org/10.1002/psb.1562

Pearlman, B. L., & Traub, N. (2011). Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. *Clinical Infectious Diseases, 52*(7), 889-900. https://doi.org/10.1093/cid/cir076

Reau, N., Vekeman, F., Wu, E., Bao, Y., & Gonzalez, Y. S. (2017). Prevalence and economic burden of extrahepatic manifestations of hepatitis C virus are underestimated but can be improved with therapy. *Hepatology communications, 1*(5), 439-452. https://doi.org/10.1002/hep4.1049

Ridruejo, E., Bessone, F., Daruich, J. R., Estes, C., Gadano, A. C., Razavi, H., ... & Silva, M. O. (2016). Hepatitis C virus infection in Argentina: Burden of chronic disease. *World Journal of Hepatology, 8*(15), 649. https://doi.org/10.4254/wjh.v8.i15.649

Ridruejo, E., Pinero, F., Mendizabal, M., Cheinquer, H., Wolff, F. H., Anders, M., ... & Latin American Liver Research Educational and Awareness Network (LALREAN). (2020). Decompensated cirrhosis and liver transplantation negatively impact in DAA treatment response: Real-world experience from HCV-LALREAN cohort. *Journal of Medical Virology, 92*(12), 3545-3555. https://doi.org/10.1002/jmv.26383

World Health Organization [WHO]. (2016). *Global health sector strategy on viral hepatitis 2016-2021*. Towards ending viral hepatitis. World Health Organization. Retrieved March 27, 2021, from https://www.who.int/publications/i/item/WHO-HIV-2016.06

World Health Organization [WHO]. (2017). *Global hepatitis report, 2017*. World Health Organization. Retrieved March 27, 2021, from https://www.who.int/hepatitis/publications/hepatitis_report2017

World Health Organization [WHO]. (2021). *Fact sheets: Hepatitis C*. World Health Organization. Retrieved March 27, 2021, from https://bit.ly/3orAfI5

Wright, M., Grieve, R., Roberts, J., Main, J., Thomas, H. C., & UK Mild Hepatitis C Trial Investigators. (2006). Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. *Health technology assessment (Winchester, England), 10*(21), 1-iii. https://doi.org/10.3310/hta10210
Copyrights
Copyright for this article is retained by the author(s), with first publication rights granted to the journal. This is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).